Investor Sofinnova Venture Partners VIII, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Sofinnova Venture Partners VIII, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-02-25 13D/A NCNA / NuCana plc - Depositary Receipt (Common Stock) 6,283,392 51,030
2024-02-27 13D/A NCNA / NuCana plc - Depositary Receipt (Common Stock) 8,081,261 6,283,392
2023-02-06 13D/A OBSV / ObsEva SA. 4,749,623 4,749,623
2022-02-28 13D/A NCNA / NuCana plc - Depositary Receipt (Common Stock) 8,045,749 8,081,261
2022-02-28 13D/A OBSV / ObsEva SA. 4,845,629 4,749,623
2021-03-04 13D/A OBSV / ObsEva SA. 4,808,486 4,845,629
2020-10-05 13D/A NCNA / NuCana plc - Depositary Receipt (Common Stock) 8,045,749 8,045,749
2020-10-03 13D/A NCNA / NuCana plc - Depositary Receipt (Common Stock) 4,712,416 8,045,749
2020-02-13 13D/A NTRA / Natera, Inc. 3,122,898 3,141,345
2020-02-13 13D/A OBSV / ObsEva SA. 4,757,956 4,808,486
2020-02-13 13G/A US74257L1089 / Principia Biopharma Inc. 2,059,146 1,438,196
2019-02-12 13G US74257L1089 / Principia Biopharma Inc. 2,059,146
2019-02-12 13G/A OCGN / Ocugen, Inc. 2,077,040 0
2019-02-12 13D/A NTRA / Natera, Inc. 3,100,560 3,122,898
2018-05-24 13D/A H03579101 / Auris Medical Holding Ltd 9,237,082 259,924
2018-02-14 13D/A SYBX / Synlogic, Inc. 574,972
2018-02-14 13D/A ACRS / Aclaris Therapeutics, Inc. 1,543,901 1,552,112
2017-10-19 13D/A OBSV / ObsEva SA. 3,751,289 4,757,956
2017-10-11 13D NCNA / NuCana plc - Depositary Receipt (Common Stock) 4,712,416
2017-04-12 13D/A INNL / Innocoll Holdings plc 2,103,173 2,103,173
2017-03-17 13D/A ARAV / Aravive, Inc. 1,658,865 1,658,865
2017-03-16 13D/A ARAV / Aravive, Inc. 1,980,412 1,658,865
2017-03-13 13D/A ARAV / Aravive, Inc. 2,361,978 1,980,412
2017-03-09 13D/A H03579101 / Auris Medical Holding Ltd 5,832,082 9,237,082
2017-02-22 13D/A INNL / Innocoll Holdings plc 2,103,173
2017-02-07 13D/A ARAV / Aravive, Inc. 2,361,978
2017-02-07 13D/A H03579101 / Auris Medical Holding Ltd 5,832,082
2017-02-06 13D OBSV / ObsEva SA. 3,751,289
2017-01-18 13D/A ACRS / Aclaris Therapeutics, Inc. 2,289,480 1,543,901
2016-12-22 13D/A ONCE / Spark Therapeutics, Inc. 1,602,983 928,238
2016-05-12 13D/A ALIM / Alimera Sciences, Inc. 2,211,604
2016-02-11 13G/A OCGN / Ocugen, Inc. 2,077,040
2015-10-21 13D/A ONCE / Spark Therapeutics, Inc. 1,602,983
2015-10-16 13D ACRS / Aclaris Therapeutics, Inc. 2,289,480
2015-10-08 13D SYBX / Synlogic, Inc. 2,976,810
2015-07-13 13D NTRA / Natera, Inc. 3,100,560
2015-02-17 13G OCGN / Ocugen, Inc. 2,077,040
2015-02-09 13D ONCE / Spark Therapeutics, Inc. 2,118,576
2014-10-29 13D/A ALIM / Alimera Sciences, Inc. 2,287,218
2014-09-19 13D/A ALIM / Alimera Sciences, Inc. 2,887,218
2014-08-13 13D H03579101 / Auris Medical Holding Ltd 5,818,175
2014-08-04 13D INNL / Innocoll Holdings plc 125,786
2014-04-07 13D ARAV / Aravive, Inc. 2,146,978
2012-10-12 13D ALIM / Alimera Sciences, Inc. 4,113,924